Stenotrophomonas maltophilia: Difference between revisions

From IDWiki
Stenotrophomonas maltophilia
()
(: added septra dose)
Line 19: Line 19:
*Therapy should be guided by antimicrobial susceptibility testing
*Therapy should be guided by antimicrobial susceptibility testing
*Antistenotrophomonal antibiotics:
*Antistenotrophomonal antibiotics:
**[[Is treated by::TMP-SMX]] (preferred agent, if susceptible)
**[[Is treated by::TMP-SMX]] 15 mg/kg split q8h (preferred agent, if susceptible)
**[[Is treated by::Fluoroquinolones]], including [[Is treated by::moxifloxacin]], [[Is treated by::levofloxacin]], and [[Is treated by::ciprofloxacin]] (though develops resistance quickly on monotherapy)
**[[Is treated by::Fluoroquinolones]], including [[Is treated by::moxifloxacin]], [[Is treated by::levofloxacin]], and [[Is treated by::ciprofloxacin]] (though develops resistance quickly on monotherapy)
**[[Is treated by::Minocycline]], [[Is treated by::doxycycline]], and [[Is treated by::tigecycline]]
**[[Is treated by::Minocycline]], [[Is treated by::doxycycline]], and [[Is treated by::tigecycline]]

Revision as of 14:07, 20 August 2020

Background

Microbiology

  • Aerobic, non-fermentive, catalase-positive, oxidase-negative, Gram-negative bacillus
  • Multiple mechanisms of resistance
    • RND, MfsA, and Sme-related efflux pumps
    • Sul or dfrA genes (TMP-SMX resistance)
    • β-lactamases
    • Aminoglycoside-modifying enzymes

Clinical Manifestations

  • Nosocomial infections with high mortality and high antibiotic resistance

Management